<DOC>
	<DOCNO>NCT01760746</DOCNO>
	<brief_summary>PDR lead cause irreversible vision loss North America . This disease cause growth abnormal blood vessel retina . These abnormal blood vessel bleed inside eye , cause vitreous hemorrhage ( VH ) . Sometimes patient bleed , surgery call vitrectomy require remove blood within eye . In order reduce complication surgery , retina surgeon inject Avastin eye day surgery . Avastin ( bevacizumab ) currently approve Health Canada treat ocular disease . Lucentis ( ranibizumab ) approve Health Canada treatment age-related macular degeneration , diabetic macular edema , retinal venous occlusive disease . While Avastin approve Health Canada treatment disease , majority retina specialist around world use Avastin `` off-label '' treat disease . That Avastin Lucentis tend work equally well disease , Avastin significantly cheap . While Avastin Lucentis generally regard equal , may differences two drug discover . The aim study look difference . Previous research investigator study show inject Avastin eyes cause increase inflammatory protein develop inside eye . This increase proteins related complication develop vitrectomy surgery . Lucentis may associate less increase inflammatory protein ( less complication ) . The aim study compare Avastin Lucentis respect affect inflammatory proteins eye , well rate complication surgery . Study participant divide two arm ( `` group '' ) 30 subject . Subjects receive Avastin Lucentis day vitrectomy surgery . The assignment random study double-masked . Masking do investigator clearly determine difference 2 drug .</brief_summary>
	<brief_title>Comparison Changes Inflammatory Proteins Aqueous Humour Subjects Treated With Avastin v Lucentis</brief_title>
	<detailed_description>60 subject take part study 2 site Canada : Vancouver ( Eye Care Centre , Vancouver General Hospital , Mount Saint Joseph Hospital ) Toronto ( Sunnybrook Health Sciences Centre ) .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . PDR vitreous hemorrhage schedule vitrectomy surgery bevacizumab pretreatment . Exclusion criterion : 1 . Vitreous hemorrhage cause central retinal vein occlusion ocular ischemic syndrome . 2 . Pregnant breastfeed woman . 3 . Less 19 year age .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
	<keyword>Vitrectomy</keyword>
	<keyword>Inflammatory Cytokines</keyword>
</DOC>